Metis Sponsors UPWARD - Huang Yulong: Shaping the Values of Our Time Through Art
20 Monumental Sculptures Transform the Urban Landscape into a Canvas
UPWARD – Huang Yulong is a groundbreaking exhibition that fuses street culture with contemporary sculpture, presented from 12 to 31 March at the Hong Kong Observation Wheel and AIA Vitality Park. Acclaimed artist Huang Yulong, known for his collaboration with international superstar Andy Lau on the Share the Love sculpture series, now presents 20 monumental sculptures. Centred around his signature hooded figure, these works serve as a powerful visual language, embodying themes of openness, diversity, community, and youth engagement.
These sculptures, standing tall with their heads lifted towards the sky, symbolise a fearless attitude towards challenges and an embrace of hope. They embody the spirit of resilience and boundless possibility, values that align with Metis' philosophy. At Metis, we believe that innovation and breakthroughs are not only the driving forces behind corporate growth but also essential catalysts for social progress. Guided by this vision, we have expanded from Hong Kong to the Asia-Pacific region, actively contributing to charitable healthcare, rural education, and cultural development. By sponsoring this renowned exhibition, Metis invites the public to experience the energy of sculptures, to feel the pulse of the era, and be inspired to fearlessly explore their own journeys and pursue their aspirations.
Corporate Engagement in Art: Expanding Cultural Influence for the Future
Dr Cheung, Founder and Chairman of Metis, stated: "This sponsorship of a contemporary art exhibition is an extension of our CSR strategy. Art and business are both rooted in innovation and value creation. Through this sponsorship, we hope to support outstanding artists, foster more profound engagement with the public, and ensure the lasting influence of culture into the future."
From healthcare and education to cultural development, Metis has remained steadfast in its commitment to giving back to society through meaningful action. By sponsoring UPWARD – Huang Yulong, we aim to inspire more enterprises to recognise the value of cultural assets and to see contemporary art as not just an artistic expression, but as a powerful catalyst for social innovation and shared values. Just as UPWARD – Huang Yulong captures the aspirations of our time through sculpture, Metis translates these values into action, working hand in hand with the art world to shape the spirit of our era and envision a better future. Through this sponsorship, we hope to set an example and encourage broader support for emerging industries and young creative talent, fostering a shared movement towards progress and leveraging art as a transformative force in defining the values of our time.
About Metis Global Group
Metis Global Group is a financial group that strives to provide unconventional trust and wealth management solutions to clients in Asia. As members of a well-established group, Metis Global (Singapore) Pte. Limited, Metis Global Limited, and Metis Global (Cook Islands) Limited offer trust solutions from jurisdictions that have well-developed trust protections which provide clients with comprehensive asset protection.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/metis-sponsors-upward--huang-yulong-shaping-the-values-of-our-time-through-art-302412745.html
SOURCE Metis Global Group
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
AM Best Revises Outlooks to Positive for The People's Insurance Company of China (Hong Kong), Limited
HONG KONG, July 18, 2025--(BUSINESS WIRE)--AM Best has revised the outlooks to positive from stable and affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of "a-" (Excellent) of The People's Insurance Company of China (Hong Kong), Limited (PICC HK) (Hong Kong). The Credit Ratings (ratings) reflect PICC HK's balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management. The ratings also reflect the strategic importance of the company to its parent, The People's Insurance Company (Group) of China Limited (PICC Group) (China). As the sole overseas insurance entity and a key component of PICC Group's overseas strategies, PICC HK receives implicit and explicit support from the parent, including business development, management personnel and financial support. The revision of the outlooks to positive from stable reflects continued improvement in PICC HK's business profile, as demonstrated by the enhanced market position and more diversified book of business. According to statistics published by its domestic regulator, PICC HK ranked 13th with a market share of 2.3% in terms of onshore and offshore combined gross premium written (GPW) in 2024. The company's GPW grew by 65% cumulatively from 2020 to 2024. The active expansion in inward reinsurance also has contributed to improved business diversification, which was concentrated moderately on a whole-account quote share (WAQS) sourced from its affiliated company, PICC Property and Casualty Company Limited (PICC P&C). The inward reinsurance business profile is diversified geographically with adequate profitability in the past four years. By leveraging the underwriting acumen and increasing synergies within the parent group, PICC HK expects the expanded business profile will be sustainable and profitable. PICC HK's risk-adjusted capitalisation, as measured by Best's Capital Adequacy Ratio (BCAR), remained at the strongest level at year-end 2024. The company's investment portfolio remains well-diversified, dominated by investment-grade bonds, cash and cash equivalents, and preference shares. Its investment strategy remains prudent, with limited exposure on unlisted funds and real-estate assets. Other supporting factors include a strong regulatory solvency position, as well as a strong liquidity position. PICC HK's operating performance remains adequate. It has maintained a mid-single digit return-on-equity ratio over the past two years. In 2024, the company's net profit was supported mainly by investment income consisting of mostly interest and dividend income. PICC HK also achieved positive underwriting results for 2024 as a result of the improved underwriting result of direct domestic business and a stable profit contribution from the WAQS. As the group's sole overseas insurance entity, PICC HK continues to be of strategic importance and plays a key role in the group's overseas strategies. There is a track record of multiple capital injections to PICC HK from PICC Group. In addition, the company continues to benefit from the group's resources and operational synergies, including business development, key management personnel, investment, information technology and overall risk management. Positive rating actions could occur if PICC HK's expanded business profile proves to be sustainable, while maintaining its underwriting profitability. Negative rating actions could occur if there is a decline in PICC HK's operating performance to a level that no longer supports AM Best's adequate operating performance assessment. Although unlikely, negative rating actions could occur if the support PICC HK receives from its parent weakens notably or the parent's credit fundamentals deteriorate materially. Ratings are communicated to rated entities prior to publication. Unless stated otherwise, the ratings were not amended subsequent to that communication. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments. AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED. View source version on Contacts Aaron Li Financial Analyst +852 2827 3426 Lucie Huang Senior Financial Analyst +852 2827 3414 Christopher Sharkey Associate Director, Public Relations +1 908 882 2310 Al Slavin Senior Public Relations Specialist +1 908 882 2318 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9%
NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial growth with the surging prevalence of chronic diseases and advancements in nuclear imaging techniques. The technetium-99m market is expected to reach US$6.29 billion by 2031 from US$ 4.61 billion in 2024; it is anticipated to register a CAGR of 3.9% during the forecast period. Technetium-99m (Tc-99m) is an extensively used radioactive isotope for diagnostic imaging in nuclear medicine. It holds the position of being the most common medical radioisotope worldwide and is used for over 40,000 imaging procedures daily in the US. To explore the valuable insights in the Technetium-99m Market report, you can easily download a sample PDF of the report - Some of the reasons behind Tc-99m's medical popularity are its ideal imaging properties, such as a short half-life of about six hours, suitable gamma energy, as well as providing a low radiation dose, giving it the capability to image organs such as the brain, heart, bones, lungs, kidneys, thyroid, and liver. The development of this market is sustained by increasing demand for Tc-99m-based radiopharmaceuticals in cardiovascular imaging and cancer detection, along with other clinical applications. North America stands as a huge market due to the advanced healthcare infrastructure and high rate of chronic diseases. Asia Pacific is growing fast owing to healthcare infrastructure investments and a focus on advanced diagnostics. The report carries an in-depth analysis of market trends, key players, and future opportunities. The technetium-99m market study focuses on an array of technologies that are expected to fuel the demand in the coming years. For Detailed Technetium-99m Market Insights, Visit: Overview of Report Findings Increasing Chronic Diseases Prevalence: The increase in prevalence of chronic diseases is a much stronger driver for the global Technetium-99m (Tc-99m) market. Tc-99m is the most important radioisotope used in more than 80% of nuclear medicine procedures in the world, mostly used in SPECT scanning for the diagnosis of cancer, cardiovascular diseases, and neurological disorders. According to the International Agency for Research on Cancer, the prevalence of cancer is high worldwide. It is estimated that there were 19.3 million cancer cases globally in 2020, and the number is expected to reach ~30.2 million by 2040. With an increase in the incidence of chronic diseases due to aging populations, sedentary lifestyles, and poor dietary habits, the demand for higher diagnostic imaging techniques rises correspondingly. Such a scenario is evident in Asia Pacific, where chronic diseases such as diabetes and cardiovascular diseases are rising. Health care providers are thus increasingly adopting technetium-based imaging techniques for early diagnosis and for planning of treatment. This rise in demand is favoring the development of the Tc-99m market. Soaring Technological Advancements: Technological discoveries open a whole new set of vistas for the Technetium-99m (Tc-99m) market by making nuclear imaging more efficient, accurate, and accessible. At the forefront of these discoveries are radiopharmaceutical production technologies that include cyclotron-based Tc-99m production that nullifies the need for assessing the aged nuclear reactors and thereby assures more stable Tc-99m supplies. In addition, imaging instrument improvement, mainly within SPECT and hybrid imaging equipment such as SPECT/CT, have increased the resolution and diagnostic ability, thereby increasing Tc-99m's clinical utility. Further, automation in radiopharmacy and simultaneous integration of digital imaging workflows minimize human errors and maximize safety and efficiency. Artificial intelligence and machine learning are further being explored and used for image analysis to provide enhanced and more rapid diagnostic capabilities. Thus, these technological advancements account for the expanding sphere of clinical applications of Tc-99m while reducing operational costs in nuclear medicine, which include its accessibility to emerging markets. Several innovations and various avenues for research, investment, and patient care are being formed in the Tc-99m market. Stay Updated on The Latest Technetium-99m Market Trends: Geographical Insights: In 2024, North America led the technetium-99m market with a substantial revenue share, followed by Europe and Asia Pacific. Further, Asia Pacific is expected to register the highest CAGR during the forecast period. Market Segmentation By application, the market is categorized into cardiovascular, bone scan, respiratory, tumor imaging, and others. The bone scan segment accounted for the largest share of the market in 2024. Based on end user, the market is segmented into hospitals, diagnostic and imaging centers, and others. The hospitals segment held the largest share of the market in 2024. The technetium-99m market is segmented into five major regions: North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: Lantheus Medical Imaging Inc., Curium, Jubilant Pharma Company, NorthStar Medical Radioisotopes LLC, Sun Pharmaceutical Industries Inc., Advancing Nuclear Medicine, NTP Radioisotopes SOC Ltd, Northwest Medical Isotopes LLC, and SHINE Technologies LLC are major companies operating in the market. Trending Topics: Emergence of Hybrid Imaging Techniques, Advancements in Radiopharmaceutical Development, and Sustainability and Cost-Effectiveness Initiatives. Purchase Premium Copy of Global Technetium-99m Market Size and Growth Report (2021-2031) at: Global Headlines on Technetium-99m Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan (Kit for the Preparation of Technetium Tc 99m Succimer Injection). BWXT Medical and Laurentis Complete Key Tc-99m Generator Program Milestone. IAEA Launches Research Project to Develop New Technetium-99m Radiopharmaceuticals. Conclusion The demand for technetium-99m is expanding at a rapid pace with increasing requirements for advanced diagnostic imaging, primarily for areas such as oncology, cardiology, and neurology. The largest market for Technetium-99m is North America followed by the easy availability of radiopharmaceuticals and higher average cost of kit for Tc-99m. The technetium-99m market in Asia Pacific is segmented into Japan, China, and India and is also expected to grow at the fastest CAGR due to the increasing investments in improving healthcare infrastructure and rising focus on advanced diagnostics. The development of imaging, such as SPECT and hybrid SPECT/CT systems, is becoming more accurate and reliable in Tc-99m using diagnostics. Furthermore, ongoing development of production technologies, such as non-reactor-based ones address Mo-99 supply chain issues, the progenitor isotope for Tc-99m. Thus, continuous advancements in imaging instruments and manufacturing technologies and government initiatives for bettering nuclear medication facilities are expected to drive the market during the forecast period. The report from The Insight Partners lists several stakeholders—including radiopharmaceutical manufacturers, medical equipment suppliers, healthcare providers, and regulatory bodies—along with valuable insights to navigate this evolving market landscape and unlock new opportunities successfully. For More Latest Life Sciences Research Reports & Industry Analysis - Trending Related Reports: Bone Scan Market Growth, Top Key Players, and Regional Forecast by 2031 Respiratory Disposable Devices Market Size, Trends, Shares, and Forecast – 2031 Respiratory Medical Device Market Size, Trends, Shares, and Forecast – 2031 Respiratory Drug Delivery Devices Market Size, Trends, Shares, and Forecast - 2031 The Tumor Embolization Market Size is expected to register a CAGR of 8.9% from 2025 to 2031 The Heart Tumor Market Size is expected to register a CAGR of 8.0% from 2025 to 2031 The Tumor Ablation Market Size is expected to register a CAGR of 12.5% from 2025 to 2031 The Respiratory Protection Equipment Market Size is expected to register a CAGR of 6.8% from 2025 to 2031 Respiratory Medical Device Professional Market Size Drivers, Opportunities, Trends, and Forecasts by 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: Phone: +1-646-491-9876 Press Release - Logo - View original content: SOURCE The Insight Partners Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Healthcare Dispensing Systems Market worth $6.27 billion by 2030 with 6.3% CAGR
DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global Healthcare Dispensing Systems Market, valued at US$4.36 billion in 2024, stood at US$4.61 billion in 2025 and is projected to advance at a resilient CAGR of 6.3% from 2025 to 2030, culminating in a forecasted valuation of US$6.27 billion by the end of the period. The market's accelerated growth trajectory is primarily driven by increasing demand for precision dispensing in pharmaceutical manufacturing, diagnostics, and medical device production. As the industry moves toward automation and miniaturization, advanced dispensing systems are streamlining workflows, improving dosing accuracy, and reducing contamination risks. Key trends such as the rise of lab-on-chip devices, personalized medicine, and point-of-care testing are expanding adoption across end-user segments. Additionally, technological innovations in microfluidics, robotics, and sensor integration are enhancing system performance. Regulatory support for digital health infrastructure and growing investment in life sciences R&D is further accelerating market expansion. Download PDF Brochure: Browse in-depth TOC on "Healthcare Dispensing Systems Market" 400 - Tables50 - Figures400 - Pages By type, the market is divided into automatic dispensing systems, semi-automated dispensing systems, stand-alone/manual dispensing instruments, and OEM/dispensing components. Automatic dispensing systems accounted for the largest share of the healthcare dispensing systems market in 2024. Their dominance is attributed to the increasing demand for high-throughput, precise, and contamination-free dispensing in diagnostic labs, pharmaceutical production, and medical device assembly. These systems are widely adopted due to their integration capabilities with automated workflows, improved operational efficiency, and reduced error rates. Advancements in tipless and non-contact dispensing, real-time data feedback, and motion control have further enhanced their appeal. Growing R&D activities, rising diagnostic volumes, and a global push for lab automation are expected to sustain the segment's leadership during the forecast period. By end user, the healthcare dispensing systems market is segmented into healthcare providers, pharma & biotech companies, MedTech companies, and other end users based on the end user. Among these, healthcare providers represent the largest segment, driven by the widespread use of dispensing systems across hospitals, diagnostic labs, outpatient centers, pharmacies, and long-term care facilities. These systems support accurate and safe medication administration, fluid handling in diagnostic workflows, and real-time inventory management. Hospitals and labs require automated dispensing to meet high patient volumes and ensure safety and quality standards compliance. The growing demand for efficient resource utilization, staff workload reduction, and integrated data systems further accelerates adoption among healthcare providers. For instance, over 90% of US acute care hospitals use Automated Dispensing Cabinets (ADCs), saving up to 35 hours of labor weekly and $64,300 annually, highlighting the strong impact of automation on hospital efficiency, cost reduction, and patient safety. As care delivery models shift toward decentralized and patient-centric approaches, healthcare providers continue to invest in dispensing systems to support scalable, connected, and efficient operations. By geography, in 2024, North America held the largest market share for healthcare dispensing systems. This dominance is due to a well-established diagnostic infrastructure, advanced pharmaceutical manufacturing capabilities, and a high concentration of biotech and medtech firms. The region benefits from substantial R&D investments, early adoption of automation, and strong support from both the government and private sector for digital transformation in healthcare. Additionally, the increasing demand for decentralized testing, the presence of major dispensing technology providers, and an emphasis on quality and regulatory compliance have all contributed to market leadership. The integration of smart dispensing solutions in diagnostics and medical device production further supports continued growth. Request Sample Pages : The prominent healthcare dispensing systems market players include Nordson Corporation (US), DH Life Sciences, LLC (US), and BRAND GMBH+Co. KG (Germany), Fisnar (US), PARKER HANNIFIN CORP (US), BioDot (US), Thermo Fisher Scientific Inc. (US), bdtronic (Germany), Agilent Technologies, Inc. (US), Hamilton Company (US), Graco Inc. (US), Imagene Technology Inc (US), Harro Höfliger Verpackungsmaschinen GmbH (Germany), Tecan Trading AG (Switzerland), IVEK Corporation (US), Revvity, Inc. (US), QIAGEN (Germany), Gilson Incorporated (US), Ascential Technologies (US), and LGC?Biosearch Technologies (UK). Nordson Corporation (US): Nordson Corporation is a key healthcare dispensing systems sector leader, leveraging its robust engineering expertise and extensive product portfolio to maintain a dominant market position. The company's global manufacturing footprint and enduring partnerships with pharmaceutical, biotech, and medical device companies reinforce its strategic advantage. Nordson delivers diverse precision dispensing solutions, specifically engineered for critical applications such as drug formulation, diagnostics production, and medical device assembly. The integration of automation, rigorous quality control measures, and strict compliance adherence into its systems solidifies its reputation as a preferred collaborator within regulated healthcare environments. Significant investment in research and development enables Nordson to continuously innovate, optimizing system precision, throughput speed, and reliability. Operating in over 35 countries across North America, Europe, Asia, and Latin America, the company provides localized support and expert technical services to its global clientele. Its deep-rooted experience in fluid management and microdispensing technologies cements Nordson's role as a pivotal enabler of high-throughput manufacturing processes within the healthcare industry. BioDot Inc. (US): BioDot Inc. is a pivotal entity in the healthcare dispensing systems sector. It is particularly recognized for its innovative ultra-low volume dispensing technologies for life sciences, diagnostics, and high-throughput manufacturing arenas. The company's expertise lies in precision fluid deposition systems, essential for applications such as point-of-care diagnostics, lateral flow assays, and biosensor development. BioDot's portfolio includes advanced solutions like the BioJet and the newly launched MODULIS platform. These systems are characterized by their integration of modular automation, intelligent conveyance mechanisms, and robust vision systems, facilitating scalable and high-volume production processes. With a footprint extending across over 50 countries, BioDot emphasizes system adaptability and manufacturing efficiency, enabling end-to-end dispensing solutions that empower manufacturers to expedite product development and shorten commercialization timelines. For more information, Inquire Now! Related Reports: Healthcare IT Market Drug Discovery Services Market Healthcare Analytics Market Healthcare IT Integration Market Microfluidics Market Get access to the latest updates on Healthcare Dispensing Systems IT Companies and Healthcare Dispensing Systems Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
